Free tool
FAERS Monitor: Rituxan Hycela
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761064 or its brand name (Rituxan Hycela, Rituximab, Hyaluronidase (Human Recombinant)). Reports on generic versions are filed under their own applications.
Reports
453
Serious
159
35% of reports
Hospitalization
66
Death reported
42
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- no adverse event88
- off label use82
- rash50
- fatigue36
- nausea35
- pain33
- headache28
- dizziness27
- pneumonia27
- dyspnoea26
- diarrhoea25
- intentional product use issue25
- malaise24
- visual impairment24
- pruritus23
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2015 | 2 |
| 2017 | 24 |
| 2018 | 71 |
| 2019 | 67 |
| 2020 | 73 |
| 2021 | 44 |
| 2022 | 34 |
| 2023 | 34 |
| 2024 | 59 |
| 2025 | 28 |
| 2026 | 17 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,706 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| no adverse eventSignal | 88 | 22.6 | 18.7 | 1,806 |
| intentional product use issueSignal | 25 | 13.3 | 9.1 | 272 |
| visual impairmentSignal | 24 | 9.0 | 6.1 | 164 |
| rashSignal | 50 | 5.3 | 4.1 | 175 |
| off label useSignal | 82 | 4.3 | 3.6 | 217 |
| pneumoniaSignal | 27 | 3.9 | 2.7 | 56 |
| pruritusSignal | 23 | 2.8 | 1.9 | 25 |
| malaiseSignal | 24 | 2.5 | 1.7 | 21 |
| dizzinessSignal | 27 | 2.5 | 1.7 | 24 |
| painSignal | 33 | 2.5 | 1.8 | 29 |
| fatigueSignal | 36 | 2.1 | 1.6 | 22 |
| dyspnoeaSignal | 26 | 2.1 | 1.5 | 15 |
| headacheSignal | 28 | 2.1 | 1.4 | 15 |
| nauseaSignal | 35 | 2.1 | 1.5 | 19 |
| diarrhoea | 25 | 1.8 | 1.2 | 8 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.